ArticleCancer cell2020
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.JCO oncology advances · 2026Article
- Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection.Lancet regional health. Americas · 2025Article
- Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.Clinical lung cancer · 2024Article
- Article
- Article
- COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.Translational oncology · 2023Article
- Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia.ESMO open · 2023Article
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.BMC cancer · 2023Article
- Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.Lancet regional health. Americas · 2023Article
- Article
- Generalizable EHR-R-REDCap pipeline for a national multi-institutional rare tumor patient registry.JAMIA open · 2022Article
- Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.Open forum infectious diseases · 2022Article
- COVID-19 vaccination and breakthrough infections in patients with cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Article
- Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.The lancet. Healthy longevity · 2022Article
- Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.JAMA network open · 2022Article
- Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.JAMA network open · 2022Article
- Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.JAMA network open · 2021Article
- The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.Journal of thrombosis and haemostasis : JTH · 2021Article
- Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.JAMA oncology · 2021Article
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.